Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial

Abstract

Neither 10-day Ecabet sodium-containing quadruple therapy or 10-day bismuth-containing quadruple therapy can be recommended as empiric therapy in cities with high antibiotic resistance rate of China.

Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies

“…Several studies have evaluated the effectiveness of adding bismuth to a standard triple therapy (Table 1). [53][54][55][56][57][58][59][60][61][62][63][64] In a recent study in a high-resistance area, H. pylori -positive patients were randomized to receive PPI-clarithromycin-amoxicillin regimen or this standard triple therapy plus bismuth for 7 days. 62 The eradication rate of the quadruple therapy group (82%) was higher than that of the triple therapy group (67%).…”

Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis

“…Only one study was included in this analysis. This study was a randomized, open‐label, phase IV trial comparing the efficacy and safety of 10‐day ecabet sodium‐containing therapy (ecabet sodium, PPI, amoxicillin, and clarithromycin) with bismuth‐containing quadruple therapy (bismuth, PPI, amoxicillin, and clarithromycin).…”

“…Several RCTs have examined the efficacy and safety of ecabet sodium as an adjuvant therapy. However, the results of these studies are controversial . Therefore, we have conducted a meta‐analysis of available data.…”

Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial

“…A previous randomized, open-label, multicenter prospective study reported a bismuth-containing quadruple therapy H . pylori eradication rate of 68% (ITT)– 77% (PP) in China [6], and sequential and concomitant therapy eradication rates of 72.1% (ITT)– 76.5% (PP) [19] and 78.3% (ITT)– 87.4% (PP) [20], respectively. Also, in vitro susceptibility of H .…”

“…The Fourth Chinese National Consensus Report on the management of H . pylori infection suggested that combining a mucosal protective agent with triple therapy may have the same efficacy as bismuth-containing quadruple therapy [6]. However, few clinical studies in China have evaluated the efficacy of adding a mucosal protective agent to enhance eradication of H .…”